CaseBioscience® rejoint l'équipe qui s'est vu attribuer jusqu'à 7,3 millions de dollars par l'ARPA-H pour faire progresser la conservation à température ambiante des thérapies cellulaires

Impact · against what's priced in

The news is moderately positive for CaseBioscience as it provides non-dilutive funding and validation from ARPA-H for its cell preservation technology. However, as there is no priced-in reconstruction available, the exact impact on the stock price cannot be measured against current market assumptions.

Scored by the NIS engine · methodology.

CaseBioscience® rejoint l'équipe qui s'est vu attribuer jusqu'à 7,3 millions de dollars par l'ARPA-H pour faire progresser la conservation à température ambiante des thérapies cellulaires

biotech▲31%
arpa h

CaseBioscience® rejoint l'équipe qui s'est vu attribuer jusqu'à 7,3 millions de dollars par l'ARPA-H pour faire progresser la conservation à température ambiante des thérapies cellulaires

What matters in this story

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL

CaseBioscience® rejoint l'équipe qui s'est vu attribuer jusqu'à 7,3 millions de dollars par l'ARPA-H pour faire progresser la conservation à température ambiante des thérapies cellulaires

What matters in this story

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL

Track these names every morning.

Water Tower Research Publishes Initiation of Coverage Report on eXoZymes, Inc., "Converting Cell-Free Science into a Scalable and Repeatable Commercial Opportunity"

Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal

ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease

IP Group banks £21m in Oxford Nanopore divestment

CaseBioscience® rejoint l'équipe qui s'est vu attribuer jusqu'à 7,3 millions de dollars par l'ARPA-H pour faire progresser la conservation à température ambiante des thérapies cellulaires

What matters in this story

Next reads from the same story arc

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL

CaseBioscience® rejoint l'équipe qui s'est vu attribuer jusqu'à 7,3 millions de dollars par l'ARPA-H pour faire progresser la conservation à température ambiante des thérapies cellulaires

What matters in this story

Next reads from the same story arc

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Anavex Life Sciences Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - AVXL

Track these names every morning.

Water Tower Research Publishes Initiation of Coverage Report on eXoZymes, Inc., "Converting Cell-Free Science into a Scalable and Repeatable Commercial Opportunity"

Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal

ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease

IP Group banks £21m in Oxford Nanopore divestment